Won Hoyoun, Kang Tae Soo, Hong Bum-Kee, Lee Seunghwan, Jeon Dong Woon, Ryu Sung Kee, Min Pil-Ki, Yoon Young Won, Lee Byoung Kwon, Kwon Hyuck Moon, Ko Young-Guk, Jang Yangsoo
aDivision of Cardiology, Gangnam Severance Hospital bDivision of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine cDepartment of Internal Medicine, Division of Cardiology, College of Medicine, Chung-Ang University dCardiology Department, Eulji General Hospital, Eulji University, Seoul eDepartment of Cardiology, Dankook University Hospital, Cheonan fDepartment of Cardiology, Wonju Severance Christian Hospital, Wonju College of Medicine, Yonsei University, Wonju gDivision of Cardiology, National Health Insurance Corporation Ilsan Hospital, Goyang, Republic of Korea.
Coron Artery Dis. 2015 May;26(3):212-9. doi: 10.1097/MCA.0000000000000195.
The aim of this study was to evaluate the extent of neointimal response after the implantation of a second-generation drug-eluting stent, zotarolimus-eluting stent (ZES-ER, Endeavor Resolute) or everolimus-eluting stent (EES, Xience V), using intravascular ultrasound (IVUS) in diabetic patients.
In all, 154 diabetic patients with de-novo coronary lesions were randomized to be implanted with a ZES-ER or EES, and the angiographic follow-up at 9 months combined with a complete IVUS study was available for 96 patients with 101 lesions.
Baseline demographic and lesion parameters were similar in both groups at index percutaneous coronary intervention. On follow-up angiography, in-stent late lumen loss and minimal lumen diameter were not different between the two groups. On IVUS study, neointimal hyperplasia volume [median (interquartile range): ZES-ER vs. EES; 2.25 mm (0.57-6.25) vs. 1.59 mm (0.45-8.37), P=0.615] and in-stent percentage of volume obstruction [median (interquartile range): ZES-ER vs. EES; 1.16% (0.33-3.61) vs. 0.77% (0.29-4.01), P=0.615] showed similar results between the two groups.
In diabetic patients, the second-generation drug-eluting stents, ZES-ER and EES, were comparable in inhibiting neointimal proliferation.
本研究旨在通过血管内超声（IVUS）评估第二代药物洗脱支架佐他莫司洗脱支架（ZES-ER，Endeavor Resolute）或依维莫司洗脱支架（EES，Xience V）植入后糖尿病患者的新生内膜反应程度。
总共154例新发冠状动脉病变的糖尿病患者被随机分配植入ZES-ER或EES，96例患者的101处病变可进行9个月的血管造影随访并结合完整的IVUS研究。
在初次经皮冠状动脉介入治疗时，两组的基线人口统计学和病变参数相似。随访血管造影显示，两组的支架内晚期管腔丢失和最小管腔直径无差异。IVUS研究显示，两组的新生内膜增生体积[中位数（四分位间距）：ZES-ER组与EES组；2.25mm（0.57 - 6.25） vs. 1.59mm（0.45 - 8.37），P = 0.615]和支架内体积阻塞百分比[中位数（四分位间距）：ZES-ER组与EES组；1.16%（0.33 - 3.61） vs. 0.77%（0.29 - 4.01），P = 0.615]结果相似。
在糖尿病患者中,第二代药物洗脱支架ZES-ER和EES在抑制新生内膜增殖方面具有可比性。
Zotero 插件